Valion Bio, Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
VBIO$0.54+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Shareholders’ Equity
Statements of Stockh olders’ Equity
(in thousands except share and per share data)
| Additional · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · Paid-in · Accumulated · Stockholders' | |||||||||
| Shares · Amount · Shares · Amount · Capital · Deficit · Equity | |||||||||
| Balances at January 1, 2023 | — | $— | 5,693 | $— | $33,272 | $(29,642) | $3,630 | ||
| Issuance of common stock, net of issuance costs | — | — | 80,543 | — | 7,560 | — | 7,560 | ||
| Issuance of warrants | — | — | — | — | 363 | — | 363 | ||
| Issuance of common stock in lieu of fractional shares for stock split | — | — | 5 | — | — | — | — | ||
| Stock-based compensation expense | — | — | — | — | 271 | — | 271 | ||
| Net loss | (8,244) | (8,244) | |||||||
| Balances at December 31, 2023 | — | $— | 86,241 | $— | $41,466 | $(37,886) | $3,580 | ||
| Issuance of common stock for restricted stock award | — | — | 442 | — | — | — | — | ||
| Issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents | — | — | 470,295 | 1 | 4,310 | — | 4,311 | ||
| Issuance of warrants | — | — | — | — | 70 | — | 70 | ||
| Stock-based compensation expense | — | — | — | — | 229 | — | 229 | ||
| Net loss | — | — | — | — | — | (5,655) | (5,655) | ||
| Balances at December 31, 2024 | — | $— | 556,978 | $1 | $46,075 | $(43,541) | $2,535 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.